secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tempest Therapeutics, Inc. (TPST)
CIK:        0001544227
Form:       8-K
Filed at:   2023-09-07T23:59:59+00:00
Accession:  0001193125-23-230659
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Tempest Therapeutics president Tom Dubensky resigns; CEO Stephen Brady to assume president role
--------------------------------------------------------------------------------

- Tom Dubensky resigned as president and board member effective Sep 2, 2023; will transition to advisor role on Sep 15, 2023.
- Resignation not due to any disagreement with Tempest on operations, policies, or practices.
- CEO Stephen Brady will be appointed as president and CEO effective Sep 15, 2023; his responsibilities unchanged.
- Dubensky expected to enter consulting agreement: $8,000 retainer for initial period (Sep 15–Oct 15), then $500/hour for services.
- Consulting period expected until at least Dec 15, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1544227/000119312523230659/0001193125-23-230659-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1544227/000119312523230659/d532461d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-230659

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer